Peer reviewed journals covering Celsion’s product and technology platforms


Phase III HEAT Study Adding Lyso-Thermosensitive Liposomal Doxorubicin to Radiofrequency Ablation in Patients with Unresectable Hepatocellular Carcinoma Lesions. Tak W-Y, Lin S-M, Wang Y, et al. Clinical Cancer Research. Published online October 10, 2017. doi: 10.1158/1078-0432.CCR-16-2433. Read More

June 13, 2017 – ThermoDox Phase III Publications, Presentations and Research Reports.
Read More

RFA plus lyso-thermosensitive liposomal doxorubicin: in search of the optimal approach to cure intermediate-size hepatocellular carcinoma. Lencioni R, Cioni D. Hepatic Oncology. Published online June 10, 2016. doi:10.2217/hep-2016-0005. Read More 

Increased duration of heating boosts local drug deposition during radiofrequency ablation in combination with thermally sensitive liposomes (ThermoDox) in a porcine model. Swenson CE, Haemmerich D, Maul DH, Knox B, Ehrhart N, Reed RA. Plos One. 2015;10(10):e0139752. doi:10.1371/journal.pone.0139752. Read More

Systemic anti-tumour effects of local thermally sensitive liposome therapy. Viglianti BL, Dewhirst MW, Boruta RJ, et al. Int J Hyperthermia. 2014;30(6):385-392. Read More

Two phase I dose-escalation/pharmacokinetics studies of low temperature liposomal doxorubicin (LTLD) and mild local hyperthermia in heavily pretreated patients with local regionally recurrent breast cancer. Zagar TM, Vujaskovic Z, Formenti S, et al. Int J Hyperthermia. 2014;30(5):285–294. Read More

Standardized radiofrequency ablation (sRFA) ≥ 45 minutes (m) plus lyso-thermosensitive liposomal doxorubicin (LTLD) for solitary hepatocellular carcinoma (HCC) lesions 3-7 cm: a retrospective analysis of phase III HEAT study. Lencioni R, Tak W-Y, Chen MH, et al. American Society of Clinical Oncology 50th Annual Meeting; May 30-June 3, 2014; Chicago, IL. Abstract e15143. Read More

Novel targeted therapy for breast cancer chest wall recurrence: low temperature liposomal doxorubicin and mild hyperthermia. Rugo HS, Zagar TM, Formenti SC, et al. Poster presented at: 2013 San Antonio Breast Cancer Symposium; December 10-14, 2013; San Antonio, TX. Abstract P4-15-05. Read More

Breast cancer recurrences at the chest wall (BCRCW) when standard treatments (Tx) have failed: lyso-thermosensitive liposomal doxorubicin (LTLD) + mild local hyperthermia (MLH). Rugo H, Formenti SC, Myerson RJ, et al. Poster presented at: European Society for Medical Oncology 37th Congress: Vienna, Austria; September 28-October 2, 2012. Abstract. Read More 

Lyso-thermosensitive liposomal doxorubicin: an adjuvant to increase the cure rate of radiofrequency ablation in liver cancer. Poon RTP, Borys N. Future Oncol. 2011;7(8):937-945. Read More

Nanoscale drug delivery and hyperthermia: the materials design and preclinical and clinical testing of low temperature-sensitive liposomes used in combination with mild hyperthermia in the treatment of local cancer. Landon CD, Park J-Y, Needham D, Dewhirst MW. Open Nanomed. 2011;(3):38-64. Read More

Lyso-thermosensitive liposomal doxorubicin: a novel approach to enhance efficacy of thermal ablation of liver cancer. Poon RT, Borys N. Expert Opin Pharmacother. (009;10(2):333-343. Read More

Phase I trial of doxorubicin-containing low temperature sensitive liposomes in spontaneous canine tumors. Hauck ML, LaRue SM, Petros WP, et al. Clin Cancer Res. 2006;12(13):4004-4010. Read More


Synthetic tumor networks for screening drug delivery systems. Prabhakarpandian B, Shen MC, Nichols JB, et al. J Control Release. 2015;201:49-55. Read More

A phase II trial of intraperitoneal EGEN-001, an IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: a Gynecologic Oncology Group study. Alvarez RD, Sill MW, Davidson SA, et al. Gynecol Oncol. 2014;133(3):433-438. Read More

Phase I trial of a formulated IL-12 plasmid in combination with carboplatin and docetaxel chemotherapy in the treatment of platinum-sensitive recurrent ovarian cancer. Anwer K, Kelly FJ, Chu C, Fewell JG, Lewis D, Alvarez RD. Gynecol Oncol. 2013;131(1):169-173. Read More

Biocompatible polymers for nucleic acid delivery. Sparks J, Anwer K. In: Domb AJ, Kumar N., Ezra A, eds. Biodegradable Polymers in Clinical use and Clinical Development. Hoboken, NJ: John Wiley & Sons, Inc.; 2011: 521-563. Read More

Phase-I clinical trial of IL-12 plasmid/lipopolymer complexes for the treatment of recurrent ovarian cancer. Anwer K, Barnes MN, Fewell J, Lewis DH, Alvarez RD. Gene Ther. Published online December 24, 2009. doi:10.1038/gt.2009.159. Read More

Treatment of disseminated ovarian cancer using nonviral interleukin-12 gene therapy delivered intraperitoneally. Fewell JG, Matar MM, Rice JS, et al. J Gene Med. 2009;11(8):718-728. Read More

Functionalized Polymers for gene therapy: Discovery, optimization and clinical development. Jeff Sparks, Jason G. Fewell, Majed Matar, Gregory Slobodkin, Jennifer Rice, Elaine Brunhoeber, Casey Pence, Danny H. Lewis, Khursheed Anwer. Presented at: 2008 National American Chemical Society Meeting; Philadelphia, PA; August 17-21, 2008. Polymer Preprints. 2008;49(2):423-424. Read More

Formulation for DNA delivery via electroporation in vivo. Anwer K. Methods Mol Biol. 2008;423:77-89. Read More

A safety and efficacy study of local delivery of interleukin-12 transgene by PPC polymer in a model of experimental glioma. Sonabend AM, Velicu S, Ulasov IV, et al. Anticancer Drugs. 2008;19(2):133-142. 2008. Read More

Synthesis and characterization of low molecular weight linear polyethylenimines for gene delivery. Matar M, Slobodkin G, Rea-Ramsey A, et al. J Biomed Nanotechnol. 2006;2(1):53-61. Read More


Up-regulation of the mammalian target of rapamycin complex 1 subunit raptor by aldosterone induces abnormal pulmonary artery smooth muscle cell survival patterns to promote pulmonary arterial hypertension. Aghamohammadzadeh R, Zhang YY, Stephens TE, et al. FASEB J. 2016;30(7):2511-2527. doi:10.1096/fj.201500042. Read More

Lipid nanoparticle delivery of a microRNA-145 inhibitor improves experimental pulmonary hypertension. McLendon JM, Joshi SR, Sparks J, et al. J Control Release. 2015;210:67-75. Read More

Genetic and hypoxic alterations of the microRNA-210-ISCU1/2 axis promote iron-sulfur deficiency and pulmonary hypertension. White K, Lu Y, Annis S, et al. EMBO Mol Med. 2015;7(6):695-713.Read More

Versatile cationic lipids for siRNA delivery. Sparks J, Slobodkin G, Matar M, et al. J Control Release. 2012;158(2):269-276. Read More

Delivery of siRNA to the mouse lung via a functionalized lipopolyamine. Polach KJ, Matar M, Rice J, et al. Mol Ther. 2012;20(1):91-100. Read More